00:00 , Aug 6, 2013 |  BC Extra  |  Politics & Policy

San Diego's Roth passes away

Duane Roth, a founding member of the executive committee of Biocom, a trade association representing life sciences companies in southern California, passed away on Aug. 3 from injuries sustained in a bicycling accident on July...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

Optison regulatory update

FDA added a boxed warning to the label of Optison to state that serious cardiopulmonary reactions, including fatalities, have occurred within 30 minutes following perflutren-containing microsphere administration. The ultrasound contrast agent, which consists of perfluoropentane-filled...
08:00 , Dec 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Dashing the hopes of buysiders,...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase IIb discontinued

ALLP discontinued a double-blind, placebo-controlled, dose-escalation, French Phase IIb trial in 128 patients in order to focus on developing Oxygent in China. Beijing Double-Crane Pharmaceutical Co. Ltd. (Beijing, China), which has Chinese rights to Oxygent,...
07:00 , May 21, 2007 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase IIb started

ALLP began a double-blind, placebo-controlled, dose-escalation, French Phase IIb trial in 128 patients undergoing primary coronary artery bypass graft (CABG) surgery under cardiopulmonary bypass (CPB). The trial will compare 1.5, 3 and 4.5 mL/kg of...
07:00 , Apr 9, 2007 |  BioCentury  |  Tools & Techniques

O, what a simple solution

Blood substitutes have been a black hole for biotech companies. There are no such products approved by FDA or EMEA after nearly two decades of effort. Nevertheless, candidates that attempt to replace the oxygen-carrying ability...
08:00 , Jan 1, 2007 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase II start

This quarter, ALLP will begin a French Phase II trial to prevent POI resulting from hypoxia during major surgery. Alliance Pharmaceutical Corp. (ALLP), San Diego, Calif.   Product: Oxygent perflubron   Business: Gastrointestinal   Molecular...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase II delayed

ALLP said the German Ethics Committee rejected an appeal to start a 65-patient Phase II trial to prevent POI resulting from hypoxia during major surgery. In August, the committee voted against the trial protocol. ALLP...
07:00 , Aug 7, 2006 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase II ongoing

The German Ethics Committee voted against letting ALLP start a 65-patient Phase II trial to prevent POI resulting from hypoxia during major surgery. ALLP said it will appeal the decision and hopes to start the...
07:00 , Apr 24, 2006 |  BC Week In Review  |  Company News

California Institute for Regenerative Medicine board of directors update

California Institute for Regenerative Medicine (CIRM), San Francisco, Calif.   Business: Other   Appointed: Duane Roth, chairman and CEO of Alliance Pharmaceutical Corp., to CIRM's oversight committee; he replaces Gayle Wilson, who resigned in January...